ATE484294T1 - Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen - Google Patents

Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen

Info

Publication number: ATE484294T1
Authority: AT; Austria
Prior art keywords: interleukin; antibodies; treatment; receptor; bronchial hyperresponsiveness
Prior art date: 1995-08-24

Application number

AT05009688T

Other languages

English (en)

Inventor

W Lee Maloy

Prasad U Kari

Nicholas Nicolaides

Original Assignee

Genaera Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-24

Filing date

1996-08-23

Publication date

2010-10-15

1996-08-23 Application filed by Genaera Corp filed Critical Genaera Corp

2010-10-15 Application granted granted Critical

2010-10-15 Publication of ATE484294T1 publication Critical patent/ATE484294T1/de

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5425—IL-9
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)

AT05009688T 1995-08-24 1996-08-23 Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen ATE484294T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US276595P	1995-08-24	1995-08-24
US2380096P	1996-08-06	1996-08-06

Publications (1)

Publication Number	Publication Date
ATE484294T1 true ATE484294T1 (de)	2010-10-15

Family

ID=26670837

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT96929657T ATE307203T1 (de)	1995-08-24	1996-08-23	Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
AT05009688T ATE484294T1 (de)	1995-08-24	1996-08-23	Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT96929657T ATE307203T1 (de)	1995-08-24	1996-08-23	Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma

Country Status (10)

Country	Link
EP (3)	EP2241329A3 (de)
JP (3)	JP3948495B2 (de)
AT (2)	ATE307203T1 (de)
AU (1)	AU6895696A (de)
CA (2)	CA2666298A1 (de)
DE (2)	DE69638281D1 (de)
DK (2)	DK1632248T3 (de)
ES (2)	ES2249786T3 (de)
PT (1)	PT1632248E (de)
WO (1)	WO1997008321A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5830454A (en) *	1996-08-30	1998-11-03	Ludwig Institute For Cancer Research	Method for treating cell mediated autoimmune disorders using interleukin-9
CA2689842A1 (en) *	1996-12-02	1998-06-11	Genaera Corporation	Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
ES2347962T3 (es) *	1996-12-02	2010-11-26	Ligand Pharmaceuticals Incorporated	Biological variability of asthma associated factor, AAF2 (IL-9 receptor), useful in treating and diagnosing atopic allergies including asthma and related disorders.
WO1998027997A1 (en) *	1996-12-20	1998-07-02	Magainin Pharmaceuticals Inc.	A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
CA2302936A1 (en) *	1997-09-19	1999-04-01	Magainin Pharmaceuticals, Inc.	Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
AU9495798A (en) *	1997-09-19	1999-04-05	Ludwig Institute For Cancer Research	Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
WO2000066708A2 (en) *	1999-05-01	2000-11-09	Magainin Pharmaceuticals, Inc.	Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
WO2002100432A1 (en)	2001-06-08	2002-12-19	Genaera Corporation	Methods for the modulation of il-13
AU2001238079A1 (en) *	2000-02-09	2001-08-20	Med Immune, Inc.	Antibody gene therapy with adeno-associated viral vectors
AU2002303098A1 (en) *	2001-02-22	2002-09-12	The Research Foundation Of State University Of New York	Opiate receptors
EP1617805A4 (de) *	2003-04-11	2012-07-04	Medimmune Llc	Verfahren zur prävention oder behandlung von atemwegserkrankungen
EP1771565B1 (de)	2004-07-20	2012-09-05	The Feinstein Institute for Medical Research	Rage protein derivate
US7635754B2 (en) *	2004-09-22	2009-12-22	Aerovance, Inc.	Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
EP1899376A2 (de)	2005-06-16	2008-03-19	The Feinstein Institute for Medical Research	Antikörper gegen hmgb 1 und fragmente davon
WO2008039941A2 (en)	2006-09-27	2008-04-03	The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services	Scgb3a2 as a growth factor and anti-apoptotic agent
JP5564167B2 (ja) *	2008-05-22	2014-07-30	日本たばこ産業株式会社	苦味マスキング剤及び苦味低減方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5208218A (en) *	1988-09-19	1993-05-04	Ludwig Institute For Cancer Research	T cell growth factor glycoproteins
US5414071A (en)	1989-05-23	1995-05-09	Genetics Institute, Inc.	Human cytokine IL-9
US5132109A (en) *	1990-10-05	1992-07-21	Ludwig Institute For Cancer Research	Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
CA2186854A1 (en)	1994-03-30	1995-10-12	William J. Alms	Human interleukin variants generated by alternative splicing

1996
- 1996-08-23 CA CA002666298A patent/CA2666298A1/en not_active Abandoned
- 1996-08-23 ES ES96929657T patent/ES2249786T3/es not_active Expired - Lifetime
- 1996-08-23 ES ES05009688T patent/ES2354360T3/es not_active Expired - Lifetime
- 1996-08-23 AU AU68956/96A patent/AU6895696A/en not_active Abandoned
- 1996-08-23 DK DK05009688.2T patent/DK1632248T3/da active
- 1996-08-23 DE DE69638281T patent/DE69638281D1/de not_active Expired - Lifetime
- 1996-08-23 CA CA002230240A patent/CA2230240C/en not_active Expired - Lifetime
- 1996-08-23 EP EP10004496A patent/EP2241329A3/de not_active Withdrawn
- 1996-08-23 JP JP51028397A patent/JP3948495B2/ja not_active Expired - Fee Related
- 1996-08-23 AT AT96929657T patent/ATE307203T1/de active
- 1996-08-23 DK DK96929657T patent/DK0846173T3/da active
- 1996-08-23 WO PCT/US1996/012757 patent/WO1997008321A1/en not_active Ceased
- 1996-08-23 EP EP96929657A patent/EP0846173B1/de not_active Expired - Lifetime
- 1996-08-23 PT PT05009688T patent/PT1632248E/pt unknown
- 1996-08-23 EP EP05009688A patent/EP1632248B8/de not_active Expired - Lifetime
- 1996-08-23 AT AT05009688T patent/ATE484294T1/de active
- 1996-08-23 DE DE69635305T patent/DE69635305T2/de not_active Expired - Lifetime
2007
- 2007-01-09 JP JP2007001870A patent/JP4813380B2/ja not_active Expired - Fee Related
2011
- 2011-02-28 JP JP2011043283A patent/JP2011152135A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE69635305T2 (de)	2006-07-06
CA2230240C (en)	2009-08-18
CA2666298A1 (en)	1997-03-06
ES2354360T3 (es)	2011-03-14
EP1632248B8 (de)	2010-12-29
EP0846173A1 (de)	1998-06-10
AU6895696A (en)	1997-03-19
ATE307203T1 (de)	2005-11-15
JP3948495B2 (ja)	2007-07-25
DE69635305D1 (de)	2006-03-02
EP2241329A3 (de)	2011-03-09
JP2007169287A (ja)	2007-07-05
PT1632248E (pt)	2010-12-28
JPH11514851A (ja)	1999-12-21
EP2241329A2 (de)	2010-10-20
JP4813380B2 (ja)	2011-11-09
DE69638281D1 (de)	2010-11-25
ES2249786T3 (es)	2006-04-01
DK0846173T3 (da)	2006-01-16
EP1632248B1 (de)	2010-10-13
EP1632248A1 (de)	2006-03-08
JP2011152135A (ja)	2011-08-11
DK1632248T3 (da)	2011-01-24
EP0846173B1 (de)	2005-10-19
WO1997008321A1 (en)	1997-03-06
CA2230240A1 (en)	1997-03-06

Legal Events

Date

Code

Title

Description

2011-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1632248

Country of ref document: EP

Publication	Publication Date	Title
ATE484294T1 (de)	2010-10-15	Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
DE3884622D1 (de)	1993-11-04	Schmiermittelzubereitung zur behandlung von rheuma.
ATA76995A (de)	2002-04-15	Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69124293D1 (de)	1997-03-06	Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
DE3772429D1 (de)	1991-10-02	Pharmazeutisches praeparat zur behandlung von peridontalkrankheiten.
DE10199020I2 (de)	2004-05-06	Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
DE69022249D1 (de)	1995-10-12	Knochenwachsapplikator zur Behandlung von Knochengewebe.
DE69616376D1 (de)	2001-11-29	Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE69526437D1 (de)	2002-05-23	Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens
DE69626539D1 (de)	2003-04-10	topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE3882775D1 (de)	1993-09-09	Zusammensetzung zur behandlung von parodontaler krankheit.
ATA902789A (de)	1995-07-15	Verfahren zur katalytischen behandlung von abwasser
DE3869590D1 (de)	1992-04-30	Mischung zur behandlung von hypercholesterolemie.
DE69004189D1 (de)	1993-12-02	Anordnungen zur behandlung menschlichen oder tierischen abfalls mittels mikrowellen.
DE69607559D1 (de)	2000-05-11	Verfahren zur Behandlung von Phenolteer
ATE213163T1 (de)	2002-02-15	Verfahren zur behandlung von motorischen defiziten
DE69729735D1 (de)	2004-08-05	Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE3856329D1 (de)	1999-06-10	Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
DE3875016D1 (de)	1992-11-05	Therapeutikum zur behandlung von aids.
DE69111324D1 (de)	1995-08-24	Vorrichtung zur Behandlung oder Trennung von Gasen.
DE69006509D1 (de)	1994-03-17	Verfahren zur behandlung von häuten.
DE3886755D1 (de)	1994-02-10	Verfahren zur behandlung von gefässkrankheiten.
ATE306278T1 (de)	2005-10-15	Behandlung von knochenleiden mit adrenomedullin
DE69521281D1 (de)	2001-07-19	Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
DE68918449D1 (de)	1994-10-27	Siliziumverbindungen zur behandlung von knochen.